NCT01830985 - A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Rheumatoid Arthritis

Interventions

DRUG

VX-509

VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)

Trial Locations (22)

Unknown

Vertex Investigational Site, Upland

Vertex Investigational Site, Fort Lauderdale

Vertex Investigational Site, Venice

Vertex Investigational Site, West Palm Beach

Vertex Investigational Site, Canton

Vertex Investigational Site, Decatur

Vertex Investigational Site, Elizabethtown

Vertex Investigational Site, Fredrick

Vertex Investigational Site, Lincoln

Vertex Investigational Site, Rochester

Vertex Investigational Site, Greensboro

Vertex Investigational Site, Duncansville

Vertex Investigational Site, Charleston

Vertex Investigational Site, Memphis

Vertex Investigational Site, Katy

Vertex Investigational Site, San Antonio

Vertex Investigational Site, Webster

Vertex Investigational Site, Spokane

Vertex Investigational Site, Tallinn

Vertex Investigational Site, Vilnius

Vertex Investigational Site, Pretoria

Vertex Investigational Site, Stellenbosch

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY